Turn Therapeutics Q3 2026 Update and GX-03 Clinical Results
Turn Therapeutics reported Phase 2a trial results for its atopic dermatitis drug GX-03, achieving high response rates. The company also provided corporate and financial updates for the third quarter of 2026.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed